Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

Jan 14, 2025 · Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneously advancing research to bring new drugs to …

Learn more about Tempus Next. Chris Scotto DiVetta, SVP of Applications at Tempus AI introduces Tempus Next, an AI enabled care pathway platform that helps providers accelerate the adoption of evidence based care. Watch replay

Jan 14, 2025 · The latest iteration of Tempus One includes four new breakthrough generative AI-powered capabilities that leverage LLMs to derive insights from unstructured data. Patient Query : Identifying and enrolling patients into clinical trials continues …

Feb 1, 2023 · We’ve built a variety of these AI-driven algorithms at Tempus. Our Tempus|TO (or tumor origin) test uses RNA expression results from tumor metastases to predict the patient’s most likely cancer type from 68 possible diagnoses.

With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx.

Sep 12, 2024 · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data.

Jan 13, 2025 · CHICAGO--(BUSINESS WIRE)--Jan. 13, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.

TEMPUS HUB. We offer a fast, reliable platform for ordering Tempus tests, accessing patient insights, and utilizing our AI-driven technologies seamlessly. TEMPUS ONE. The first generative AI-enabled clinical assistant that provides access to patient insights directly at your fingertips. EHR INTEGRATION